Cargando...
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease,...
Gardado en:
| Publicado en: | Ann Clin Transl Neurol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497536/ https://ncbi.nlm.nih.gov/pubmed/28695150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.410 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|